| Jacqueline Vo, MD | |
|
2204 Austin St Ste 200, Houston, TX 77002-8912 | |
| (713) 640-5477 | |
| Not Available |
| Full Name | Jacqueline Vo |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 26 Years |
| Location | 2204 Austin St Ste 200, Houston, Texas |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346338001 | NPI | - | NPPES |
| H084445001 | Other | TX | BCBS |
| 7104482 | Other | TX | AETNA |
| 9978456 | Other | TX | CIGNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | M2179 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rheumatology Center Of Houston, Pllc | 3779767074 | 3 |
News Archive
Medworxx Solutions Inc. today announced a partnership with Leidos Health (formerly part of SAIC and includes the businesses of former maxIT Healthcare and Vitalize Consulting Solutions) which formalizes their agreement to leverage each organization's global expertise in patient flow optimization.
The Senate gave final approval to a bill Monday that gives federal regulators greater oversight of compounding pharmacies like the ones responsible for a deadly meningitis outbreak last year. The President is expected to sign the bill.
Neuralstem, Inc. announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Intravenous bevacizumab should be considered as a first-line therapy for the treatment of refractory bleeding in patients with severe hereditary hemorrhagic telangiectasia, reports Mayo Clinic Proceedings
› Verified 4 days ago
| Entity Name | Rheumatology Center Of Houston, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568769248 PECOS PAC ID: 3779767074 Enrollment ID: O20110412000074 |
News Archive
Medworxx Solutions Inc. today announced a partnership with Leidos Health (formerly part of SAIC and includes the businesses of former maxIT Healthcare and Vitalize Consulting Solutions) which formalizes their agreement to leverage each organization's global expertise in patient flow optimization.
The Senate gave final approval to a bill Monday that gives federal regulators greater oversight of compounding pharmacies like the ones responsible for a deadly meningitis outbreak last year. The President is expected to sign the bill.
Neuralstem, Inc. announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Intravenous bevacizumab should be considered as a first-line therapy for the treatment of refractory bleeding in patients with severe hereditary hemorrhagic telangiectasia, reports Mayo Clinic Proceedings
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jacqueline Vo, MD 2204 Austin St Ste 200, Houston, TX 77002-8912 Ph: (713) 640-5477 | Jacqueline Vo, MD 2204 Austin St Ste 200, Houston, TX 77002-8912 Ph: (713) 640-5477 |
News Archive
Medworxx Solutions Inc. today announced a partnership with Leidos Health (formerly part of SAIC and includes the businesses of former maxIT Healthcare and Vitalize Consulting Solutions) which formalizes their agreement to leverage each organization's global expertise in patient flow optimization.
The Senate gave final approval to a bill Monday that gives federal regulators greater oversight of compounding pharmacies like the ones responsible for a deadly meningitis outbreak last year. The President is expected to sign the bill.
Neuralstem, Inc. announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Intravenous bevacizumab should be considered as a first-line therapy for the treatment of refractory bleeding in patients with severe hereditary hemorrhagic telangiectasia, reports Mayo Clinic Proceedings
› Verified 4 days ago
Dr. Michaela Elizabeth Ginn, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 13214 Indian Creek Road, Houston, TX 77079 Phone: 713-591-3555 Fax: 661-321-3286 | |
Ameena Bagree Malhotra, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, 77030-4009, Houston, TX 77030 Phone: 713-792-6161 | |
Svetang Vijay Desai, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 444 Fm 1959 Rd, Suite A, Houston, TX 77034 Phone: 281-481-9400 | |
Dr. Stalin R Subramanian, M.D Rheumatology Medicare: Medicare Enrolled Practice Location: 7200 Cambridge St Fl 8, Houston, TX 77030 Phone: 713-798-0950 | |
Robin Boliver-campbell, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 7141 Southwest Fwy, Houston, TX 77074 Phone: 713-771-7921 Fax: 713-264-8659 | |
Henna Mukhtar Malik, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 13215 Dotson Rd Ste 300, Houston, TX 77070 Phone: 281-894-8822 | |
Zaven Sargsyan, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1504 Taub Loop, Houston, TX 77030 Phone: 713-873-8890 |